Source facts
FDA issued an approval letter for EBANGA on 2026-02-19. The source metadata identifies BLA 761172 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
EBANGA — FDA Approval Letter (BLA 761172)
Issued to RIDGEBACK BIOTHERAPEUTICS. Application is approved as submitted.
Issued
February 19, 2026Application
BLA • 761172
Product
EBANGA
Company
RIDGEBACK BIOTHERAPEUTICS
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for EBANGA?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: BLA 761172.
- 3Submission: supplement.
- 4Sponsor: RIDGEBACK BIOTHERAPEUTICS.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the EBANGA approval letter
Is EBANGA FDA approved?
This letter documents an FDA approval action: FDA approved BLA 761172 for EBANGA, sponsored by RIDGEBACK BIOTHERAPEUTICS, on February 19, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is BLA 761172?
BLA 761172 is the application under which FDA issued this approval letter for EBANGA to RIDGEBACK BIOTHERAPEUTICS. The letter is dated February 19, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.